K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting compone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hofmann, Irmgard, Weiss, Andreas, Elain, Gaelle, Schwaederle, Maria, Sterker, Dario, Romanet, Vincent, Schmelzle, Tobias, Lai, Albert, Brachmann, Saskia M., Bentires-Alj, Mohamed, Roberts, Thomas M., Sellers, William R., Hofmann, Francesco, Maira, Sauveur-Michel
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432074/
https://ncbi.nlm.nih.gov/pubmed/22952903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados